Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia
NCT00950430Phase 4Enrolling by invitation
- Sponsor
- Mayo Clinic
- Start
- Apr 2008
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of carbon-11 Pittsburgh compound B in Alzheimer's disease (AD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), vascular dementia, sponsored by Mayo Clinic. Started Apr 2008; status: enrolling by invitation.
02
Drugs
carbon-11 Pittsburgh compound B
03
Conditions
Alzheimer's disease (AD)dementia with Lewy bodies (DLB)frontotemporal dementia (FTD)vascular dementia
Beyond the preview
Go deeper on NCT00950430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00950430.